[Is there a place for treatment with type 5 phosphodiesterase inhibitors in heart failure patients?]

Kardiol Pol. 2011;69(9):952-7.
[Article in Polish]
No abstract available

Publication types

  • Review

MeSH terms

  • Carbolines / therapeutic use
  • Heart Failure / drug therapy*
  • Humans
  • Imidazoles / therapeutic use
  • Phosphodiesterase 5 Inhibitors / therapeutic use*
  • Piperazines / therapeutic use
  • Purines / therapeutic use
  • Randomized Controlled Trials as Topic
  • Sildenafil Citrate
  • Sulfones / therapeutic use
  • Tadalafil
  • Treatment Outcome
  • Triazines / therapeutic use
  • Vardenafil Dihydrochloride

Substances

  • Carbolines
  • Imidazoles
  • Phosphodiesterase 5 Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Triazines
  • Vardenafil Dihydrochloride
  • Tadalafil
  • Sildenafil Citrate